Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak wątroby (biopsja lub badania obrazowe)
- •Wiek od 18 do 75 lat
- •Tumor można całkowicie usunąć chirurgicznie
- •Brak przerzutów w innych organach
- •Wcześniej nie leczono lekami ukierunkowanymi na raka wątroby
- •Wystarczająca funkcja wątroby, nerek i krwi
- •Spodziewana życliność co najmniej 12 tygodni
- •Wysoki risk nawrotu: wiele guzów lub wznowienie się w naczyniach żylnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Trial contact
Ze-yang Ding, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.